Tarsus Pharmaceuticals (TARS – Research Report) received a Buy rating and a $40.00 price target from H.C. Wainwright analyst Oren Livnat today. The company’s shares closed last Monday at $24.13, close to its 52-week low of $21.00.
According to TipRanks.com, Livnat is a 2-star analyst with an average return of 1.0% and a 41.3% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Verrica Pharmaceuticals, and Zynerba Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tarsus Pharmaceuticals with a $57.00 average price target.
Based on Tarsus Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.24 million and GAAP net loss of $15.7 million. In comparison, last year the company had a GAAP net loss of $10.14 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company’s lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.
Read More on TARS:
- Vir Biotechnology (VIR) Gets a Buy Rating from H.C. Wainwright
- H.C. Wainwright Thinks TOMI Environmental Solutions’ Stock is Going to Recover
- Goldman Sachs Reaffirms Their Hold Rating on Clariant AG (CLZNF)
- H.C. Wainwright Remains a Hold on Summit Therapeutics (SMMT)
- H.C. Wainwright Sticks to Their Buy Rating for DBV Technologies SA – American (DBVT)